Recent Activity

Filter by:

All

• 

  The Long Tail of Cancer Research "What's really amazing about the Long Tail is the sheer size of it. Combine enough nonhits on the Long Tail and you've got a market bigger than the hits." Source: Chris Anderson, Wired The other other day, while barely lucid...

  ~1 month on
  Pharma Strategy Blog
• 

  Fluid-based early detection biomarkers in cancer A really interesting idea that seems to be growing in popularity is the concept of fluid-based biomarkers from blood, urine, saliva etc, as opposed to invasive tumour biopsies. A recent paper in Cancer Research took a look at this novel...

  ~1 month on
  Pharma Strategy Blog
• 

  Monday Mumblings - Life in the fast lane After taking a week off work decompressing without a laptop (yes really), I've been catching up on my reading over the weekend and browsing the long list of diverse blogs that I follow from tech to venture capital, sports, science,...

  ~1 month on
  Pharma Strategy Blog
• 

  On clinical trials, creativity and patient adherence in cancer "Let us honour if we can The vertical man Though we value none But the horizonatal one." WH Auden Over the last few months, I've been having some interesting conversations with various people involved with cancer research and have been...

  ~1 month on
  Pharma Strategy Blog
• 

  Wishing America a happy July 4th! By the time you all read this, I will be off somewhere on holiday for the week, or vacation as they prefer to say on this side of the pond. Many of my consulting friends grumble about the slowdown in...

  2 months on
  Pharma Strategy Blog
• 

  Combined NOTCH and EGFR inhibition leads to synthetic lethality in breast cancer This was a great paper I found while browsing My 6 Sense last night, a free but very cool app on my iPhone that takes my Google Reader rss feeds and intuitively tries to select the individual items (e.g. clinical...

  2 months on
  Pharma Strategy Blog
• 

  Advancing the Use of Biomarkers in Cancer Drug Development This was the title of a fascinating article I saw on Twitter a few minutes ago, courtesy of the American Association of Cancer Research (AACR). They are providing access to the paper free of charge to the public using this...

  2 months on
  Pharma Strategy Blog
• 

  Celgene buy Abraxis Bioscience for $2.9B I did a double take at my inbox alerts this morning as things have been rather quiet of late in the Pharma and Biotech world. You can read the financial aspects of the deal in Celgene's press release. While the...

  2 months on
  Pharma Strategy Blog
• 

  How cognitive surplus will change the world: Clay Shirky Here's an interesting and informative TED video I just came across, where Clay Shirky talks about cognitive surplus and how it will change the world. The idea behind the concept of "cognitive surplus" is that we use spare brain cycles...

  2 months on
  Pharma Strategy Blog
• 

  Gefitinib or Chemotherapy for Non–Small Cell Lung Cancer with Mutated EGFR AstraZeneca's Gefitinib (Iressa) has had a bit of a chequered history since it's fast track approval by the the Japanese Health Authority in 2002 and the FDA in 2003 for non-small cell lung cancer (NSCLC). However, since the phase III...

  2 months on
  Pharma Strategy Blog
• 

  New imaging technique shows promise in detection of Alzheimer's Disease "Dr. Skovronsky thought he had a way to make scans work. He and his team had developed a dye that could get into the brain and stick to plaque. They labeled the dye with a commonly used radioactive tracer and...

  2 months on
  Pharma Strategy Blog